"uuid:ID","description","text","label","id","instanceType","name"
"557cd9f8-ece1-444e-8650-5cb4d00d0723","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective_1","Objective","OBJ1"
"b8d18860-351e-42c7-963e-4da597aba382","Safety","To document the safety profile of the xanomeline TTS.","","Objective_2","Objective","OBJ2"
"a4579fb1-fb57-4bd5-b18b-2c386f1c445c","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective_3","Objective","OBJ3"
"e780f2b5-fea9-403d-b1c6-8026a8591675","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective_4","Objective","OBJ4"
"43697c1f-9c65-4853-9a16-38835aea6b66","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective_5","Objective","OBJ5"
"674f4936-93aa-48ba-a75c-b023a7d44ac7","","To assess the treatment response as a function of Apo E genotype.","","Objective_6","Objective","OBJ6"
